Acorda monetizes Fampyra royalties for $53 million

18 November 2017

Acorda Therapeutics (Nasdaq: ACOR), which last week suffered a significant setback with its Phase III program of Parkinson’s disease drug tozadenant, on Friday announced a $40 million royalty monetization with HealthCare Royalty Partners (HCR) and a $13 million royalty monetization with Denmark’s Lundbeck (LUN: C).

In return for the payment to Acorda, HCR obtains the right to receive royalty revenue on Fampyra (prolonged-release fampridine tablets) payable by Biogen, up to an agreed upon threshold of royalties. After this threshold is met, if ever, Acorda will continue to receive Fampyra royalty revenue until this revenue stream ends. The transaction does not include potential future milestones to be paid by Biogen (Nasdaq: BIIB).

Lundbeck and Acorda have amended the license agreement for Selincro (nalmefene) to eliminate future royalty and milestone obligations on sales of Selincro outside of the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK